Takeaway

• The  KRAS p.G12C inhibitor sotorasib offers benefit for patients with NSCLC.
• The phase 2 CodeBreaK 100 trial of sotorasib yielded an objective response rate (ORR) of 37.1% for patients with pretreated  KRAS  p.G12C-mutated NSCLC.

Why this matters

• The  KRAS  p.G12C mutation is a therapeutic challenge with no approved targeted treatment.
• Mature...